NCT06215430View on ClinicalTrials.gov

A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 11, 2021

Primary Completion Date

April 15, 2021

Study Completion Date

April 15, 2021

Conditions
Healthy
Interventions
DRUG

Caffeine Tablet

Administered orally.

DRUG

Omeprazole capsule

Administered orally.

DRUG

Warfarin tablet

Administered orally.

DRUG

Pirtobrutinib

Administered orally.

Trial Locations (1)

75247

Covance Clinical Research Unit, Dallas

Sponsors

Collaborators (1)

Loxo Oncology, Inc.
All Listed Sponsors
collaborator

Loxo Oncology, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT06215430 - A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants | Biotech Hunter | Biotech Hunter